Latest News and Press Releases

Four new members enhance independence and diversity of Board of Directors Alvotech (NASDAQ and First North Growth Market: ALVO), a global biotech company specialized in the development and...

Fjölbreyttari samsetning stjórnar með aðkomu óháðra stjórnarmanna Alvotech (NASDAQ og First North Growth „ALVO“) tilkynnti í dag um fjölgun í stjórn fyrirtækisins, í tengslum við skráningu...

AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studiesEylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10 billion...

AVT06 er þriðja líftæknilyfjahliðstæða Alvotech sem tekin er til klínískrar rannsóknarGert er ráð fyrir að um 444 sjúklingar taki þátt í rannsókninni Eylea® (aflibercept) er lyf við augnsjúkdómum en...

AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studies Eylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10...

The board of directors of Alvotech (the “Company”) has resolved to increase the Company´s share capital by an amount of two hundred seventy thousand seven hundred twenty-one US dollars and sixty-seven...

After the largest debut by an Icelandic company on a U.S. stock exchange, Alvotech is set to list its shares under the ticker symbol “ALVO” on the Nasdaq First North Growth Market in Iceland...

In connection to the filling on Form 20-F with the U.S. Securities and Exchange Commission (SEC),  Alvotech has published a supplement dated 22 June 2022 to the Company Description, dated 21 June...

Í tengslum við birtingu á formi 20-F hjá bandaríska verðbréfaeftirlitinu (SEC) þá hefur Alvotech birt viðauka dagsettan 22. júní 2022 við skráningarskjal félagsins dagsett 21. júní 2022. Við birtingu...

Alvotech, a public limited liability company (société anonyme), incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273...